Abstract 19P
Background
Breast cancer is the commonest cancer among women requires multimodality treatment including adjuvant radiotherapy for better loco regional control. Long term toxicity to heart and lung following chemotherapy especially anthracyclines and Trastuzumab.Deep inspiratory breath-hold technique is a state of art technique for reducing heart doses without compromising target coverage or other organ-at-risk. The technique is based upon the observation that during inspiration, the flattening of the diaphragm and expansion of the lungs pulls the heart away from the chest wall. Surface guided radiotherapy (SGRT) is a magnificent devise helps us to do deliver and monitor radiotherapy with DIBH technique easily. This study explores the benefit of using DIBH with SGRT in left sided breast cancer radiotherapy treatment.
Methods
Eighty four breast cancer patients (both BCS and MRM), received adjuvant radiotherapy, between December 2019 and February 2022 were studied in this study. Patients were immobilized using breast boards with both arms positioned above the head. All patients had 2 sets of planning CT images (one in FB and another in DIBH) with a HD CT scanner in the same positional setup.Doses to the target and OARs and patient’s positional shits with three point laser and Align RT (VisionRT) surface guided RT were compared. The standard fractionation regimen of 50Gy in 25 fractions over a period of 5 weeks was used for all patients in this study.
Results
Among Eighty-four enrolled patients, average Dmean, V5%, V10%, V30% to heart with DIBH is 6.27 Gy, 33.04 GY, 19.49 Gy, 3.85Gy respectively. Average Dmean, V5%, V10%, V30% to heart with free breathing is 8.87Gy, 42.2 Gy, 29.9 Gy, 4.9Gy. which shows a statistically significant reduction in dose delivered to heart by using DIBH technique. Average dose to lung in terms of V30 Gy, V20Gy, V12Gy, V5Gy with DIBH is observed to be 24.38%, 28.9%, 36.51%, 48.98% respectively. While using FB technique lung doses in terms of V30 Gy, V20Gy, V12Gy, V5Gy with DIBH is observed to be 27.86%, 32.74, 37.58, 49.45 respectively.
Conclusions
Surface guided radiotherapy helps in precise positioning and patient monitoring which aims at more accurate treatment delivery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institutional Review Board.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
16P - The prognostic value of androgen receptor expression in triple-negative breast cancer patients
Presenter: Rasha Haggag
Session: Poster viewing 01
17P - Clinical, pathological complete response and prognosis characteristics of HER2-low breast cancer in neoadjuvant chemotherapy setting: A retrospective analysis
Presenter: Hui Liu
Session: Poster viewing 01
18P - Low levels of miR-18a is associated with immunosuppression and increased chemo-unresponsiveness in ER-negative tumors
Presenter: Madhumathy Nair
Session: Poster viewing 01
20P - Physician perceptions to use of trastuzumab in HER2+ breast cancer in India
Presenter: Nagendra Ramanjinappa
Session: Poster viewing 01
23P - Combination chemotherapy and hormone therapy (CHT) in patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): A single-centre retrospective analysis
Presenter: Kripa Bajaj
Session: Poster viewing 01
24P - Outcomes of patients with HER2 positive metastatic breast cancer treated with low dose or metronomic lapatinib
Presenter: Sherin Mathew
Session: Poster viewing 01
25P - Absolute lymphocyte count as prognostic factor in patients with metastatic breast cancer: A systematic review and meta-analysis
Presenter: Dhea Hermanto
Session: Poster viewing 01
26P - Circulating osteocalcin-positive cells, as a novel biomarker for monitoring the therapeutic effects on bone metastasis
Presenter: Min Joo Kim
Session: Poster viewing 01
27P - Outcomes analysis of the effect of an educational activity on the knowledge and confidence of oncologists regarding emerging antibody drug conjugates for the treatment of breast cancer
Presenter: Nabil Dorkhom
Session: Poster viewing 01
28P - Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu-expressing breast cancer patients
Presenter: Yogesh Rathore
Session: Poster viewing 01